Ozempic is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Novo Nordisk. The primary component is Semaglutide.
Product ID | 0169-4136_16fb5f2c-ad9e-4a1e-9a82-6c888cd7fe13 |
NDC | 0169-4136 |
Product Type | Human Prescription Drug |
Proprietary Name | Ozempic |
Generic Name | Semaglutide |
Dosage Form | Injection, Solution |
Route of Administration | SUBCUTANEOUS |
Marketing Start Date | 2017-12-06 |
Marketing Category | NDA / NDA |
Application Number | NDA209637 |
Labeler Name | Novo Nordisk |
Substance Name | SEMAGLUTIDE |
Active Ingredient Strength | 1 mg/mL |
Pharm Classes | GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2017-12-06 |
Marketing End Date | 2023-10-31 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA209637 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2017-12-06 |
Marketing Category | NDA |
Application Number | NDA209637 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2017-12-06 |
Ingredient | Strength |
---|---|
SEMAGLUTIDE | 1.34 mg/mL |
SPL SET ID: | adec4fd2-6858-4c99-91d4-531f5f2a2d79 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0169-4130 | Ozempic | semaglutide |
0169-4132 | Ozempic | semaglutide |
0169-4136 | Ozempic | semaglutide |
0169-4181 | Ozempic | semaglutide |
0169-4772 | Ozempic | semaglutide |
50090-5138 | Ozempic | semaglutide |
50090-5139 | Ozempic | semaglutide |
70518-2143 | Ozempic | Ozempic |
0169-4501 | WEGOVY | semaglutide |
0169-4505 | WEGOVY | semaglutide |
0169-4517 | WEGOVY | semaglutide |
0169-4524 | WEGOVY | semaglutide |
0169-4525 | WEGOVY | semaglutide |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
OZEMPIC 79159431 4774881 Live/Registered |
Novo Nordisk A/S 2014-12-03 |